- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Femasys Inc.: Femasys to Exhibit at The Canadian Fertility and Andrology Society's 70th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Di | Femasys Inc.: Femasys to Participate in Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
| 29.08. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | Femasys Inc.: Femasys Announces CE Mark and Canadian Approval for FemVue MINI, a Fallopian Tube Assessment Solution | 97 | GlobeNewswire (Europe) | ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 27.08. | Femasys Inc.: Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters | 1 | GlobeNewswire (USA) | ||
| 09.08. | Femasys reports Q2 results | 2 | Seeking Alpha | ||
| 08.08. | Femasys stock target cut to $12 amid sales headwinds | 2 | Investing.com | ||
| 08.08. | FEMASYS INC - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.08. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08. | Femasys Inc.: Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update | 93 | GlobeNewswire (Europe) | ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office... ► Artikel lesen | |
| 05.08. | VirtaMed entwickelt Simulatoren für Femasys | 1 | punkt4.info | ||
| 12.07. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 27.06. | Femasys Inc.: Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam | 1 | GlobeNewswire (USA) | ||
| 20.06. | Deep Dive Into Femasys Stock: Analyst Perspectives (4 Ratings) | 3 | Benzinga.com | ||
| 20.06. | FEMASYS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | EXCLUSIVE: Femasys At Inflection Point And Undervalued, Expects Growth Potential Following Roe v. Wade Overturn, CEO Says | 2 | Benzinga.com | ||
| 17.05. | Femasys Inc.: Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative | 2 | GlobeNewswire (USA) | ||
| 16.05. | Femasys Inc.: Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House's Gender Policy Council | 1 | GlobeNewswire (USA) | ||
| 09.05. | Femasys GAAP EPS of -$0.17, revenue of $0.27M | 2 | Seeking Alpha | ||
| 09.05. | FEMASYS INC - 10-Q, Quarterly Report | 1 | SEC Filings |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTUITIVE SURGICAL | 425,55 | 0,00 % | Unglaubliche Prognose für Montag setzt Intuitive Surgical Aktionäre unter Druck. Jetzt Sondermeldung lesen und Montag reagieren! | ||
| ROKU | 58,39 | +0,59 % | 3 Reasons to Buy Roku Stock Like There's No Tomorrow | ||
| ATOSSA THERAPEUTICS | 1,170 | -2,82 % | Atossa Therapeutics, Inc.: Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference | ||
| EVOFEM BIOSCIENCES | - | - | Evofem faces delisting as stock price falls below $0.01 | ||
| EMEIS | 7,565 | -0,33 % | Jean-Marc Boursier Appointed emeis' Chief Financial Officer | Regulatory News:
emeis (Paris:EMEIS):
Effective 2 September, Jean-Marc Boursier joins Laurent Guillot and his management team as Group Chief Financial Officer (CFO). Jean-Marc will take over... ► Artikel lesen | |
| QUIDELORTHO | 36,800 | -6,12 % | Why QuidelOrtho Stock Blasted 10% Higher Today | ||
| TEMPEST THERAPEUTICS | 1,151 | +3,32 % | Tempest Therapeutics: Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference | ||
| VERU | 0,819 | +6,44 % | Veru Inc.: Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results | --Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected... ► Artikel lesen | |
| CENTENE | 67,63 | +5,85 % | Investoren meiden heute das Wertpapier von Centene: Kurs gibt deutlich nach (66,9345 €) | Am US-amerikanischen Aktienmarkt fällt derzeit die Centene-Aktie negativ auf. Das Papier verbilligt sich heute deutlich. Zu den Flops des Tages des Tages gehört heute die Centene-Aktie mit einem Minus... ► Artikel lesen | |
| NANO-X IMAGING | 5,885 | -1,59 % | Nano-X Imaging Ltd. (NNOX): An Under The Radar AI Stock You Should Pay Attention To | ||
| LANTHEUS | 91,94 | 0,00 % | Lantheus expands board with biotech veteran Julie Eastland | ||
| PERSPECTIVE THERAPEUTICS | 15,330 | -0,58 % | Perspective Therapeutics: FDA Grants Fast Track Designation For Development Of 212Pb VMT01 | ||
| TEMPUS AI | 49,920 | -10,26 % | Tempus AI Signs Real World Data Collaboration With BioNTech To Support Oncology Pipeline | BERLIN (dpa-AFX) - Tempus AI, Inc (TEM), a technology company using AI to advance precision medicine and patient care, Wednesday announced a multi-year real world data collaboration with BioNTech... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 46,200 | 0,00 % | AMN Healthcare Services Inc. Q2 Profit Decreases, But Beats Estimates | WASHINGTON (dpa-AFX) - AMN Healthcare Services Inc. (AMN) announced earnings for second quarter that decreased from last year but beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
| OMNICELL | 40,000 | -2,44 % | EVE Energy Co., Ltd.: EVE Energy Reveals Advanced Omnicell 6C Fast-Charging Battery that Can Reach 300km Driving Range with Five Minutes Charging | With a refreshed brand vision, EVE Energy will continue to expand commercial applications of its lithium batteries to include smart living, green transportation, energy transformation, and... ► Artikel lesen |
Das Unternehmen FEMASYS INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 1,120 Euro und damit +1,82 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FEMASYS INC finden Sie auf Wallstreet Online.
